The aim of this study was to determine the minimal core length to be taken per cc of prostate volume for an effective prostate biopsy.
Patients and Methods
A retrospective analysis was performed on the records of 379 patients who underwent a first prostate biopsy with 12 to 16 cores under transrectal ultrasound guidance between September 2012 and April 2015. For each patient, the core length per cc of the prostate and the percentage of sampled prostate volume were calculated, and these values were compared between the patients with and without prostate cancer.
A total of 348 patients were included in the study. Cancer was determined in 26.4% of patients. The mean core length taken per cc of prostate and the percentage of sampled prostate volume were determined to be 3.40 ± 0.15 mm/cc (0.26%; range, 0.08-0.63 cc) in patients with cancer and 2.75 ± 0.08 mm/cc (0.20%; range, 0.04-0.66 cc) in patients without cancer (P = .000 and P = .000), respectively. Core length taken per cc of prostate of > 3.31 mm/cc was found to be related to an increase in the rates of prostate cancer diagnosis (odds ratio, 2.84; 95% confidence interval, 1.68-4.78). The rate of cancer determination for core length taken per cc of prostate of < 3.31 mm/cc was 19.9% and of > 3.31 mm/cc, 41.1%.
Core length taken per cc of prostate and the percentage of sampled prostate volume are important morphometric parameters in the determination of prostate cancer. The results of study suggest a core length per cc of the prostate of > 3.31 mm/cc as a cutoff value for quality assurance.
To read this article in full you will need to make a payment
Purchase one-time access:Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
One-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:Subscribe to Clinical Genitourinary Cancer
Already a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
- Extended peripheral zone biopsy schemes increase cancer detection rates and minimize variance in prostate specific antigen and age related cancer rates: results of a community multi-practice study.J Urol. 2003; 169: 125-129
- Optimizing prostate cancer detection: 8 versus 12-core biopsy protocol.J Urol. 2009; 182: 1329-1336
- Systematic 5 region prostate biopsy is superior to sextant method for diagnosing carcinoma of the prostate.J Urol. 1997; 157 (discussion: 202-3): 199-202
- Optimizing performance and interpretation of prostate biopsy: a critical analysis of the literature.Eur Urol. 2010; 58: 851-864
- Twelve prostate biopsies detect significant cancer volumes (> 0.5 mL).BJU Int. 2000; 85: 705-707
- Random systematic versus directed ultrasound guided transrectal core biopsies of the prostate.J Urol. 1989; 142 (discussion: 74-5): 71-74
- Extensive biopsy using a combined transperineal and transrectal approach to improve prostate cancer detection.Int J Urol. 2005; 12: 959-963
- The effect of prostate volume on the yield of needle biopsy.J Urol. 1998; 160: 1718-1721
- Contemporary role of systematic prostate biopsies: indications, techniques, and implications for patient care.Eur Urol. 2013; 63: 214-230
- Core length in prostate biopsy: size matters.J Urol. 2012; 187: 2051-2055
- Length of prostate biopsy cores: does it impact cancer detection?.Can J Urol. 2013; 20: 6848-6853
- An extended 10-core transrectal ultrasonography guided prostate biopsy protocol improves the detection of prostate cancer.Eur Urol. 2004; 45 (discussion: 448-9): 444-448
- Comparison of 8, 10, 12, 16, 20 cores prostate biopsies in the determination of prostate cancer and the importance of prostate volume.Can Urol Assoc J. 2014; 8: E81-E85
- Comparison of 3 different methods of anesthesia before transrectal prostate biopsy: a prospective randomized trial.The J Urol. 2004; 172: 502-505
- Three-Tesla magnetic resonance-guided prostate biopsy in men with increased prostate-specific antigen and repeated, negative, random, systematic, transrectal ultrasound biopsies: detection of clinically significant prostate cancers.Eur Urol. 2012; 62: 902-909
- Can 3-Tesla pelvic phased-array multiparametric MRI avoid unnecessary repeat prostate biopsy in patients with PSA < 10 ng/mL?.Clin Genitourin Cancer. 2015; 13: e27-e30
- Comparison of MR/ultrasound fusion-guided biopsy with ultrasound-guided biopsy for the diagnosis of prostate cancer.JAMA. 2015; 313: 390-397
- Needle core length in sextant biopsy influences prostate cancer detection rate.Urology. 2002; 59: 698-703
- Can we obtain better specimens with an end-cutting prostatic biopsy device?.Eur Urol. 2005; 47: 297-301
- Initial extended transrectal prostate biopsy–are more prostate cancers detected with 18 cores than with 12 cores?.J Urol. 2008; 179 (discussion: 1331): 1327-1331
- Optimization of initial prostate biopsy in clinical practice: sampling, labeling and specimen processing.J Urol. 2013; 189: 2039-2046
- The utility of apical anterior horn biopsies in prostate cancer detection.Urol Oncol. 2003; 21: 361-365
- Clinical value of core length in contemporary multicore prostate biopsy.PLoS One. 2015; 10: e0123704
- Extended 21-sample needle biopsy protocol for diagnosis of prostate cancer in 1000 consecutive patients.Eur Urol. 2007; 52: 430-435
Published online: February 24, 2016
Accepted: February 14, 2016
Received in revised form: February 4, 2016
Received: November 17, 2015
© 2016 Elsevier Inc. All rights reserved.